Billiontoone (NASDAQ:BLLN) Insider Nancy Joann Johnson Sells 10,582 Shares of Stock

Billiontoone, Inc. (NASDAQ:BLLN) insider Nancy Joann Johnson sold 10,582 shares of the business’s stock in a transaction dated Tuesday, June 9th. The stock was sold at an average price of $100.47, for a total transaction of $1,063,173.54. Following the completion of the sale, the insider directly owned 21,900 shares of the company’s stock, valued at $2,200,293. The trade was a 32.58% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Nancy Joann Johnson also recently made the following trade(s):

• On Monday, June 8th, Nancy Joann Johnson sold 3,418 shares of Billiontoone stock. The stock was sold at an average price of $99.28, for a total transaction of $339,339.04.

Billiontoone Trading Down 3.1%

NASDAQ BLLN opened at $99.26 on Thursday. The company has a debt-to-equity ratio of 0.18, a quick ratio of 10.58 and a current ratio of 10.92. Billiontoone, Inc. has a one year low of $61.96 and a one year high of $138.70. The company has a 50-day simple moving average of $87.26 and a 200-day simple moving average of $88.18. The firm has a market capitalization of $4.57 billion and a PE ratio of 180.47.

Billiontoone (NASDAQ:BLLN) last announced its quarterly earnings data on Wednesday, May 6th. The company reported $0.34 earnings per share for the quarter, beating analysts’ consensus estimates of $0.01 by $0.33. The business had revenue of $108.39 million for the quarter, compared to the consensus estimate of $95.81 million. During the same period in the prior year, the company earned ($0.39) EPS. Billiontoone’s quarterly revenue was up 83.8% on a year-over-year basis. On average, equities analysts forecast that Billiontoone, Inc. will post 0.93 earnings per share for the current year.

Analysts Set New Price Targets

BLLN has been the subject of a number of recent research reports. Guggenheim boosted their price objective on shares of Billiontoone from $100.00 to $120.00 and gave the company a “buy” rating in a research report on Wednesday, May 13th. BTIG Research lowered their price objective on shares of Billiontoone from $140.00 to $130.00 and set a “buy” rating for the company in a research report on Thursday, May 7th. Weiss Ratings downgraded shares of Billiontoone from a “sell (d+)” rating to a “sell (d)” rating in a research report on Friday, June 5th. JPMorgan Chase & Co. boosted their price objective on shares of Billiontoone from $120.00 to $125.00 and gave the company an “overweight” rating in a research report on Thursday, May 7th. Finally, Wall Street Zen raised shares of Billiontoone from a “hold” rating to a “buy” rating in a research note on Saturday, March 7th. Six analysts have rated the stock with a Buy rating, three have given a Hold rating and one has given a Sell rating to the stock. According to MarketBeat, Billiontoone currently has an average rating of “Moderate Buy” and a consensus target price of $125.29.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently bought and sold shares of the company. Rossby Financial LCC acquired a new position in Billiontoone during the 4th quarter valued at about $25,000. Wells Fargo & Company MN acquired a new stake in shares of Billiontoone in the 4th quarter worth approximately $76,000. Smartleaf Asset Management LLC acquired a new stake in shares of Billiontoone in the 4th quarter worth approximately $80,000. Nano Cap New Millennium Growth Fund L P acquired a new stake in shares of Billiontoone in the 4th quarter worth approximately $82,000. Finally, Renaissance Capital LLC acquired a new stake in shares of Billiontoone in the 4th quarter worth approximately $201,000.

About Billiontoone

BillionToOne (NASDAQ: BLLN) is a molecular diagnostics company that develops and commercializes high-precision genetic testing solutions based on single-molecule counting technology. The company’s platform is designed to detect and quantify rare genetic variants and chromosomal abnormalities from cell-free DNA, with a primary focus on applications in prenatal screening and other clinical genetic tests where sensitivity and specificity at very low allele fractions are critical.

BillionToOne’s offerings center on assay development and clinical testing workflows that enable non-invasive prenatal testing (NIPT) and targeted molecular diagnostics.